Joel Greenblatt Acadia Pharmaceuticals Inc Transaction History

Gotham Asset Management, LLC

$16.1 Billion
Q2 2025

A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Gotham Asset Management, LLC holds 17,607 shares of ACAD stock, worth $368,690. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,607

Previous 34,074 48.33%

Holding current value

$368,690

Previous $565,000 32.92%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$14.1 - $22.95 $232,184 - $377,917	-16,467 Reduced 48.33%	17,607 $379,000
Q1 2025 May 15, 2025	SELL	$16.61 - $20.29 $596,166 - $728,248	-35,892 Reduced 51.3%	34,074 $565,000
Q4 2024 Feb 14, 2025	BUY	$14.29 - $18.76 $489,289 - $642,342	34,240 Added 95.84%	69,966 $1.28 Million
Q3 2024 Nov 14, 2024	BUY	$15.14 - $19.14 $77,653 - $98,169	5,129 Added 16.76%	35,726 $549,000
Q2 2024 Aug 14, 2024	BUY	$14.62 - $18.42 $447,328 - $563,596	30,597 New	30,597 $497,000
Q2 2020 Aug 13, 2020	SELL	$39.26 - $52.73 $273,838 - $367,791	-6,975 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$31.65 - $46.87 $274,816 - $406,972	-8,683 Reduced 55.45%	6,975 $295,000
Q4 2019 Feb 14, 2020	SELL	$36.21 - $51.4 $447,700 - $635,509	-12,364 Reduced 44.12%	15,658 $670,000
Q3 2019 Nov 14, 2019	BUY	$22.22 - $44.01 $622,648 - $1.23 Million	28,022 New	28,022 $1.01 Million
Q4 2017 Feb 14, 2018	SELL	$26.84 - $39.14 $1.04 Million - $1.52 Million	-38,843 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$29.49 - $38.37 $1.15 Million - $1.49 Million	38,843	38,843 $1.46 Million

Others Institutions Holding ACAD

# of Institutions

348

Shares Held

163M

Call Options Held

811K

Put Options Held

334K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $3.39B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account